The role of etanercept in ankylosin spondylitis

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Davis Jr , John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankylosing spondylitis; Controlled trial; Human; TNF; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INFLAMMATORY DISEASE; INJECTION SITE; NEUROTOXICITY; NONHUMAN; PHYSICAL DISABILITY; PRIORITY JOURNAL; SIDE EFFECT; SPINE DISEASE; TREATMENT FAILURE; ADULT; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SAFETY; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 0036402840     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. KEFFER J, PROBERT L, CAZLARIS H et al.: Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. Embo J 1991; 10: 4025-31.
2. CREW MD, EFFROS RB, WALFORD RL, ZELLER E, CHEROUTRE H, BRAHN E: Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998; 18: 219-25.
3. GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-31.
4. TOUSSIROT E, LAFFORGUE P, BOUCRAUT J et al.: Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-80.
5. CANETE JD, LLENA J, COLLADO A et al.: Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997; 36: 38-42.
6. GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-10.
7. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
8. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
9. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
10. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
11. MEASE P, KIVITZ A, BURCH F, SIEGEL E, COHEN S, BURGE D: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter trial. Arthritis Rheum 2001; 44: S90.
12. MEADOR RJ HSIA EC, KITUMNUAYPONG T, SCHUMACHER HR: Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis? Arthritis Rheum 2001; 44: S348.
13. MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7.
14. BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 29: 118-22.
15. REIFF A, HENRICKSON M: Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis (JAS). Arthritis Rheum 2001; 44: S292.
16. GORMAN JD, SACK KE, DAVIS JC JR: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349.
17. VAN DER HEIJDE D, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S, BELLAMY N: Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999; 26: 951-4.
18. ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.